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Abstract
Electronic medical records (EMRs) were primarily introduced as a digital health
tool in hospitals to improve patient care, but over the past decade, research works
have implemented EMR data in clinical trials and omics studies to increase transla-
tional potential in drug development. EMRs could help discover phenotype-
genotype associations, enhance clinical trial protocols, automate adverse drug event
detection and prevention, and accelerate precision medicine research. Although
feasible, data mining in EMRs still faces challenges. Existing machine learning tools
may help overcome these bottlenecks in EMR mining to unlock new approaches in
drug development. This chapter will explore the role of EMRs in drug development
while evaluating the viability and bottlenecks of their uses in data mining. This will
include discussions on EMR usage in drug development while highlighting success-
ful outcomes in oncology and exploring ML tools to complement and enhance EMR
as a widely accepted drug-research source, a section on current clinical applications
of EMRs, and a conclusion to summarize and imagine what a future drug research
pipeline from EMR to patient treatment may look like.
Keywords: drug research and development, machine learning, AI, electronic
medical records, EMR, EHR, NLP, deep learning, big data, data analysis,
data-mining
1. Introduction
Advances in Artificial Intelligence methods have skyrocketed in the past decade,
especially in the medical space where the impact of healthcare reaches individuals
across a broad spectrum of communities. In particular, machine learning (ML)
researchers have gained access to a large quantity of high quality medical data,
aggregated by health providers as a result of implementing hospital management
systems. A crucial element of these management systems is electronic medical
records (EMRs), which are rich in valuable real world data on patient, clinical and
genomic data. An EMR is a digitized record of a medical occurrence documented
either during or after an encounter by a medical professional in a medical environ-
ment. For example, the results of a blood test administered at a hospital may be part
of an EMR. Clinical notes taken by the doctor in a routine check-up at a local clinic are
also included in the EMR. EMRs can come in the form of structured data such as drug
1
orders, medications, laboratory tests and diagnosis codes or unstructured data such as
text-based clinical progress notes, radiology reports and pathology findings [1].
When EMRs are amalgamated to create a longitudinal overview of a specific
patient, this larger unit of digitized records is called an electronic health record
(EHR). Since EHRs contain historical data, they are used to track the health pro-
gression of patients over time. Although in some sources, the terms EMR and EHR
are used interchangeably, or are sometimes referred to as the electronic patient
record, for simplicity the above definitions are used here. Another digital record is
the personal health record, which is the electronic medical data that the individual
may choose to provide to the medical institutions or health providers, however
issues of personal choice in volunteering data are beyond the scope of this chapter,
so we do not consider the personal health record here.
Today, providers produce EMRs with the hope to provide a centralized source of
medical data, which helps increase care coordination. With a standardized EMR
system, if an individual decides to switch health providers, the medical data can
seamlessly transfer to the new institutions. Furthermore, centralized medical data
reduces duplication of records and identifies missing patient data, which reduces
valuable time spent in clinical care. Compared to the traditional paperwork, EMRs
significantly decreases disease identification time, making healthcare more time
efficient and cost effective [2, 3]. In this sense, the EMRs improve quality of care.
In reality, there are issues in introducing EMRs into healthcare provider systems
such as implementation and workflow disruptions. Implementation requires
funding, necessary staff, and up to date digital technology. Institutions and geo-
graphic regions with ample resources will benefit from this implementation. How-
ever, for many smaller scale practices, implementation is not financially viable. For
regions where institutions do not have access to technology that enables the pro-
duction, storage and sharing of EMRs, this concept does not make sense. Further-
more, workflow is disrupted when clinicians and other medical professionals must
alter their workflow in order to complete these documents. EMRs are notoriously
unpopular in the medical community as it burdens professionals to constantly type
on their computer instead of caring for their patients. Burdened professionals do
not see the long term benefits and the reality in medical environments is that EMRs
are primarily used for financial and administrative purposes. For example, although
there are no global standards to what may be included in an EHR, it must always
have billing codes, which are used for administrative purposes such as reimburse-
ment or auditing reasons.
Despite these institutional challenges, EMRs are gaining traction in the biomed-
ical space because there is potential to extract important biomedical conclusions
from EMRs. As of December 2019, there are just under 2.1 million papers published
on electronic medical records in drug development and research within google
scholar [4]. Because EMRs are untapped and vast in quantity, researchers are
particularly focused on testing ML methods on EMRs. EMRs also provide resources
to carry out clinical trials at a lower cost and with reduced duration in terms of
efficiency gained from automation and having better data sources. With a manual
approach to identify and extract high value data, drug research on EMRs are not
scalable and are extremely costly to employ domain experts for data extraction. The
push for medical document digitization in conjunction with recent development in
ML methods, such as natural language processing (NLP) that allows for machines to
mimic human comprehension of written text, has allowed the outsourcing of these
research tasks to machines and further facilitate drug research.
In the context of ML methods, EMRs pose problems such as how EMRs do not
have a standardized formatting, how minorities could be underrepresented, and
how EMRs contain human errors. Today in the healthcare space, EMRs exist in
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abundance but were not originally created with a large scale data-mining vision [5].
Rather, providers replaced paper-work with electronic records to keep up with the
technological pace of the 21st century. Such digitization of the traditional paper-
work was done on an ad-hoc basis and many healthcare institutions independently
regulate EMRs to create a highly heterogeneous data set [6, 7]. This heterogeneity
makes data pre-processing for ML methods time consuming and financially costly if
domain experts are required for this task. Another difficulty stems from the issue of
institutions and geographic regions not having access to technology or financial
resources to implement EMRs. The lack of EMRs in particular communities means
those individuals are not electronically visible. In this sense, EMRs will not be able
to sample certain populations in the world. These underrepresented populations
will not have as much benefit from the biomedical success of EMRs as those
represented in the sample populations, increasing the inequality of medical care.
Lastly, basic human error in the EMRs will affect analysis performed on these data
sets, if they are not corrected. In addition, the EMRs come from different institu-
tions, which may enter their data differently. Without a standardized requirement
for EMRs, some parts will be missing core information and the operation is not
scalable.
1.1 Chapter overview
This introduction started with a brief discussion of what an EMR is and how
we define it in the absence of international unifying standards. This chapter will
now move on to an overview of how machine learning techniques, applied to
EMRs, are influencing three key areas of biomedical research and drug discovery:
(1) phenotype-genotype associations, (2) clinical trials, and (3) pharmacovigilance.
Firstly, we assess the impact of EMRs on making accurate phenotype-genotype
associations, where physical traits are linked to specific locus in the genome. We
then look at EMRs in the context of clinical drug trials and pharmacovigilance,
which together amount to the tracking of a drug’s efficacy and adverse side-effects
both before and after it is licensed and used. Finally, a number of different case
studies are looked at in detail, and we present a vision of how integrated EMRs and
ML-driven EMR drug research could be implemented in the future.
2. EMRs and phenotype-genotype association research
Phenotype-genotype association is the correspondence between a person’s
genetic makeup—their genotype, and the observable characteristics or pathologies
that are a product of their genetics interacting with the environment—their pheno-
type. In the medical space, researchers study phenotype-genotype associations
because variations in the human genome affect how a person exhibits phenotypic
traits, so to understand phenotype-genotype relations is to have biological insight
into disease mechanisms. Furthermore, phenotype-genotype associations are
important in drug discovery because phenotype targets are used to identify viable
drug targets within the human genome and are needed to understand the chemistry
of a potential drug within the human biology. Understanding phenotype-genotype
associations has useful downstream applications in many fields including disease
categorization, phenotype discovery, pharmacogenomics, drug–drug interaction
(DDI), and adverse drug event (ADE) detection, and genome-wide and phenome-
wide association studies [8].
Phenotype-genotype association research owes its foundation to the genome-
wide association studies (GWAS) studies that were driven by the potential of
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genetic variations modulating disease risks, expression and progression. Although
the GWAS studies accumulated vast amount of genetic data, a remaining challenge
is translating genetic markers to its associated phenotype [9, 10]. A high-
throughput solution to such challenge is to harness phenotype data embedded in
EMRs.
In a medical provider setting, clinical professionals observe phenotypes on a
daily basis to diagnose diseases because phenotypic traits are manifestations of an
individual’s genome interacting with the environment. Such diagnosis is recorded
extensively in EMRs, making them rich in phenotype-related data. Following the
human genome project and the following development in sequencing whole
genomes, EMRs can now feasibly link an individual’s genome as part of their
medical data.
However, linking genomic data to EHRs is not common in clinical practice. This
is due to the combination of clinics offloading new sequencing technology to bioin-
formatics laboratories and the lack of infrastructure for integrating the processed
genomic data into EHRs [11]. Unlike most clinical laboratory tests, genomic testing
requires data curation during the bioinformatics pipelines. Therefore, when labora-
tories send genomic tests back to the original provider, the format or structure of
that data may not be directly compatible with the local EHR system [12]. In 2016,
laboratories were still physically mailing or faxing genomic reports in PDFs, which
is a format that is extremely difficult for machines to read and interpret [12]. This
clinical hurdle aside, in biomedical research this genomic inclusion in EHRs shows
potential in secondary use as raw data from which to draw medically meaningful
results [2, 12, 13]. Assuming that the EMR has adequate phenomic and genomic data
on an individual, algorithms can translate raw data in EMRs to phenotype data,
which in turn can be associated with the genomic data.
This section will focus on studies that cover phenotype-genotype research using
EMRs that aims to advance drug research, with particular attention to the machine
learning methods used in these cases. In a broad sense, this phenotype-genotype
application of EMRs to drug research has two major tasks. First is to identify
phenotypes contained in EMRs and second is to extract the phenotype to genotype
associations.
One of the validated processes to identify phenotypic traits from EMRs is the use
of standardized codes. Standardized codes have been designed for specific medical
needs and are heavily used in the structured documentation in EMRs. When com-
posing EMR’s, medical professionals use an internationally standardized set of codes
for reporting disease and health conditions called the International Classification of
Disease (ICD) developed by the World Health Organization (WHO). For example,
the ICD code may be a procedure code that indicates what medical procedures a
patient has received during hospitalization or a disease code that specifies a clini-
cian’s diagnosis. Although standardized, the recorded ICD relies on a consistent
interpretation of the ICD criteria for accuracy and relevancy, which will inevitably
vary between clinicians, departments and institutions. However, researchers cir-
cumvent the larger issue of heterogenous EMR data types, which might range from
character strings in clinical notes to matrices of pixels in radiology images, by
focusing on these codes that are a standardized part of EHRs.
In the context of AI, using standardized codes is advantageous because they
vastly reduce the set of possible inputs to any given machine learning algorithm.
In practical terms, the data requires little pre-processing, since the codes already
contain accurate and rich medical information described by domain experts. Com-
putation becomes scalable as less pre-processing means less manual work involved,
which is a necessity when extracting phenotypic data. Inevitably, there are a multi-
tude of competing standards. As mentioned earlier, the ICD is consistently updated
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in order to internationally keep track of morbidity and mortality statistics with its
eleventh version being adopted and replacing previous revisions starting 1 January
2022 [14]. In addition to the ICD, the US government has designed the ICD Clinical
Modification (ICD-CM), which is based upon ICD but tailored to the US healthcare
market. The Clinical Classification Software for ICD-CM, developed by the US
Agency for Healthcare Research and Quality, is a further development to the ICD-
CM that regroups codes into clinically relevant categories. New standards do not
have to be based upon existing ones, however. Phecodes is a standard specifically
designed for biomedical research and to facilitate phenome-wide association stud-
ies, first published in 2010 [15, 16]. In 2017, these different sets of standardized
EMR codes (ICD, ICD-CM, phecodes) were compared based on their ability to
create correctly pair single nucleotide polymorphism (SNP), which is a nucleotide
level genetic variation, to the corresponding phenotype, and it was found that the
phecodes performed markedly better than the ICD based standards [15, 17]. It is
perhaps not surprising that the phecodes performed best. Phecodes were developed
for research purposes, whereas ICD and related standards are more focused on
record keeping and streamlining the financial aspect of healthcare. These results
illustrate how common EMR codes used in hospitals are not well designed for ML
purposes. Although these codes are a convenient aspect within the context of
diverse data from EMRs, care must be taken when designing algorithms, which
repurpose the codes for phenotype extraction.
EMRs often contain a mixture of standardized codes and free-text. To improve
upon methods that only consider codes, machine learning tools, largely based upon
NLPs, have been developed to collect more phenotypic data from data sources
beyond standardized codes such as textual clinical notes, textual discharge summa-
ries and radiology reports [1, 18–21]. Liao et al. developed a multimodal automated
phenotyping (MAP) algorithm to leverage both ICD codes and EMR textual narra-
tives based on the Unified Medical Language System [18]. MAP is multimodal
because it can extract entities such as ICDs, medical NLP concepts and healthcare
utilization information related to a certain phenotype from both codes and free text.
Using MAP, Liao et al. analyzed those entities by different latent mixture models to
predict whether a patient had a certain phenotypic feature. Liao et al. ran the
algorithm through a validation dataset that contained labelled data with one of 16
unique phenotypes to show that MAP can extract relevant and phenotype-specific
entities at comparable accuracy to those identified by a manual approach (AUC-
MAP = 0.943, AUC-manual = 0.941). Another example of successful high through-
put method to extract phenotypes from EMRs is PheNorm, which harnesses stan-
dardized codes as training labels and does not require domain experts to label the
training set, making the model highly scalable and cost effective for phenotype
research [19]. In the face of the ML hype, it is naive to say that ML methods are
superior and domain experts will become superfluous in the future. For example,
Coquet et al. demonstrated the use of NLP methods and a Convolutional Neural
Network (CNN) method to create word embeddings in clinical notes to automate
clinical phenotyping of prostate cancer patients [20]. In this particular case, the
phenotyping accuracy of CNN model (F-measure = 0.918) surpassed that of the
rule-based model (F-measure = 0.897) [20] and the authors concluded that the
mixture of both models can lead to even better precision and accuracy. These
statistics in which the CNN model, which is a class of deep neural networks,
outperformed the rule-based model, an example of human driven modelling where
domain knowledge is needed, is indicative of the potential in ML methods but
human expertise is still needed to attain even higher accuracy and precision.
The next stage after phenotype extraction is to create phenotype-genotype asso-
ciations. In addition to the development of higher quality and more available
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electronic medical records, EHRs can now be matched with biopsies stored in
biobanks through patient-specific identifiers making it possible to study genetic and
phenotypic data alongside clinical findings. Earlier studies focused on using statis-
tical methods, such as the proof of concept study done by Denny et al. to develop a
method to scan phenomic data for genetic associations using ICD billing codes [16].
Subsequent studies have shown the viability of using ML algorithms to understand
phenotype-genotype associations using EMR sources with most of the papers
published in the past year [22, 23]. Recently, deep learning gained popularity as an
accurate framework at identifying phenotype-genotype associations [24].
Boudellioua et al. takes a deep neural network and developed an OpenSource
phenotype-based tool called DeepPVP, which prioritizes potential causative vari-
ants from whole genome sequence data [25]. As another example, Zeng et al. used
Bayesian network learning to extract epistatic interactions, which are gene-to-gene
interactions that change exhibited phenotypic traits, that effect breast cancer
patient survival on 1981 EHRs taken from the METABRIC dataset [26]. Their model
learned SNP associations that effect breast cancer patient survival that agreed with
domain knowledge from breast cancer oncologists [26]. Furthermore, unsupervised
learning has also been recognized as a great tool to discover new phenotypes [27].
Stark et al. studied the unsupervised extraction of phenotypes from cancer clinical
notes to use in association studies and reported success in finding new phenotype-
genotype association hypothesis that are not published but plausible from a biolog-
ical perspective [27]. Positive results form many recent studies demonstrates how
deep learning shows promise in phenotype-genotype association extraction.
Such high performing machine learning on big data to create phenotype-
genotype associations give hope to the future of personalized medicine, which is
healthcare tailored to different variations in a genotypes. More basic biomedical
research on phenotype-genotype associations opens possibilities for selecting best
treatments and for studying drugs that come back with negative or adverse results.
However, getting to such advanced levels of drug research is still on the horizon as
there are still more challenges in finding phenotype-genotype associations.
As mentioned before, one of the major problems is that EMRs generally suffers
from the difficulty in identification and correction of missing or mistaken data. In
many cases, ML methods require large datasets and when EHRs are amalgamated
from multiple sources, a high number of varying kinds of errors are carried over to
the data set and therefore propagate through to the algorithms. Due to the high
throughput of data in ML methods, there is a need for an automatic correction
filter, or a complete work around the missing data. One solution to missing EMR
data is to identify the missing phenotype data and correct it using a combination of
bioinformatics and genomic data [28, 29]. Even with sparse numbers of high quality
phenotypic or genotypic data, there has been studies that have successfully
extracted phenotype-genotype information from EMR using semi-supervised, bulk
phenotyping framework, and NLP-based machine learning techniques [24, 30, 31].
Another method to tackle missing data is to use a machine learning model to
completely encompass the missing data as part of the training set and therefore
accept the sparsity as part of the valid data [32]. Another solution is to acknowledge
the missing data as a variable in the modelling of the algorithm and quantify its
predicted effects on the final results and conclusion [33].
In summary, EMRs are a vital source of information in basic biomedical science,
specifically for phenotype-genotype associations, and there is a trend to test ML
methods on this untapped and vast data set to overcome the challenges EMRs face
during data mining. The advantage of EMRs is that it can be mined for phenotypes
and linked to genomic data. The section discussed different types of standardized
codes used in EMRs, which are easy to pre-process for ML frameworks. Codes such
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as ICDs, ICD-CM, and phecodes showed that they can successfully and conve-
niently identify phenotypes. However, standard codes used by providers were not
intended for data-mining purposes and therefore see performance issues when they
are used outside their primary objective, to identify phenotypes. To harness EMR
data beyond codes, studies look at a mixture of ICDs and free text. In the context of
phenotype identification, this blend of data sources showed high performance
especially when using ML methods in conjunction with more rule-based methods
that require domain expertise. Furthermore, this section discussed the strong via-
bility of ML methods for phenotype-genotype association identification, with a
trend toward using deep learning frameworks. EMR applications through ML
methods still face the problem of missing or erroneous data, which may affect the
subsequent biomedical conclusions. Further work is being done to combat the
shortcomings discussed and overall, EMRs have proven to be a promising data
source for phenotype-genotype related research.
3. EMR use in clinical trials
Clinical research informatics has emerged in the last 5–6 years as a new field of
biomedical translational research, which revolves around using informatics
methods to collect, store, process and analyze real-world clinical data to further
biomedical research purposes. With the increasing availability of such electronic
data and the development of analysis tools, EMRs can help decrease the cost and
time of clinical trials by automating patient recruitment, extend randomized control
trials and enhance retrospective cohort studies.
Clinical trials are a crucial stage in drug development to test for drug safety and
efficacy. These trials are time consuming, labor intensive and costly to operate, and
a significant bottleneck for many trials is insufficient patient enrollment [34].
However, by harnessing the data contained within EMRs, clinical trials can become
more efficient by automating recruitment and having a more extensive view of
medical data compared to the traditional manual search. Successful examples have
shown that EMR mining for potential recruitment are more cost efficient and less
time consuming than traditional methods [35, 36]. As a quantitative example, a
study done in the US studied 31 EHR-driven analysis on drug-to-genome interac-
tions and concluded that EHRs helped decrease the trial cost by 72% per subject and
reduced the duration of the studies [13].
It is also possible to repurpose systems that already exist within a clinical setting
to improve trial recruitment. A study conducted by Devoe et al. repurposed an
already existing Best Practice Alert (BPA) system, which was originally intended to
improve patient care by automating basic keyword searches on patient EHRs, to
recruit potential trial participants for a COPD study [37, 38]. Devoe et al. directly
compared the cost effectiveness of the BPA-driven screening to that of the tradi-
tionally manual method, namely the EMR Reporting Workbench method where
clinicians customize a query through a platform in order to pull data from the EHR
database, and concluded that BPA was four times faster at screening all patients and
ultimately lead to a projected 442.5 h reduction over the course of the study.
A particularly interesting case of a commercial EMR product developed for
research purposes used in a clinical setting is a platform called InSite. This Software
as a Service platform was developed out of the Electronic Health Record for Clinical
Research (EHR4CR) project (completed Spring 2016), which aimed to create a
secure, robust and scalable platform used around Europe to create a network of safe
and security-compliant real world data, which can be reuse to further clinical
research [39]. International research groups and medical providers from multiple
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countries developed this platform and intended for researchers to interact with
hospital-based EHRs. A study by Claerhout et al. studied the feasibility of using
InSite as a tool to estimate numbers of eligible participants for clinical trials at 24
European hospitals [40]. They studied the inclusion and exclusion (I/E) criteria of
protocols from 23 trials across diverse therapeutic areas, including ABP 980 and
trastuzumab for early breast cancer, a combination of cediranib and chemotherapy
in relapsed ovarian, fallopian tube or epithelial cancer, and selumetinib in combi-
nation with docetaxel for metastatic lung cancer. These clinical trials were spon-
sored by various pharmaceutical companies 1 to represent key I/E criterion using
terms included in the standard medical coding systems 2 [40]. It was found that a
median of 55% of the I/E criteria can be translated to InSite queries using the
standard medical coding systems to correctly identify potential trial patients. This
result is promising as it shows the feasibility of translating the complex protocol
criteria into machine-readable queries via an already existing platform.
This success of patient identification is attributed to how well defined the disease
parameters are in the I/E criterion and whether its clinical concepts exactly match a
query that the InSite platform can digest. Unfortunately, these queries do not contain
easily accessible nor standardized temporal information on disease development such
as the rapid progression of a tumor size or the timing at which an operation was carried
out. This lack of temporal resolution led to the lowest formalization rate (38%) in
patients with metastatic melanoma, revealing the difficulty of acquiring temporal
information on tumor staging and genetic testing [40]. A possible next step to this
study is to harness NLP to the unstructured EMR data and to resolve the temporal
issue in order to increase performance in patient recruitment. Overall, this study
showed the potential for this commercialized platform for optimizing recruitment by
hospitals. Beyond the feasibility of estimating the number of potential trial patients,
this platform is advantageous because InSite offers a convenient and efficient way for
researchers can access real-time clinical data by extracting relevant EMRs without
disrupting healthcare providers with new technological implementations.
It has been shown that NLP [34] is able to reduce the amount of manual-driven
patient identification required. Once the number of patients eligible for a clinical
trial is estimated, the next step is to carry out patient screening on each individual.
There are three methods that can carry out these checks. Meystre et al. harnessed
NLP to directly compare clinical trial screen accuracy between machine learning,
rule-based and cosine-similarity based methods and reported the highest accuracy
(micro-averaged recall 90.9%) and precision (89.7%) for the machine learning
method [34]. In such automations, the usage of NLP and harnessing machine
learning is key to fully automating cohort selections using EHRs, and there are
research done to further those tools, which is illustrated with the emergence of
CREATE [41] and SemEHR, which is an open source semantic search and analysis
tool for EMRs [42]. Such automations revolutionize clinical trial processes by cut-
ting down administrative work by an order of magnitude. To deal with the ever
increasing amount of EMR data made available, case studies have also shown that
unsupervised ML methods may be used to identify disease cohort selection with
high accuracy compared to the traditional and manual methods [43].
In some cases, EMRs can allow for more diversity in clinical trials and provide
data collection on individuals that are traditionally underrepresented, such as racial
minorities, children, rural communities or pregnant women [35, 44, 45]. However,
1 Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, F-Hoffman La Roche, Janssen, Sanofi.
2 Diagnosis: ICD-10CM, procedures: ICD-PCS, medication: ATC, laboratory: LOINC, clinical findings:
SNOMED and anatomic pathology/oncology ICD-O-3.
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there are also studies that published poor performance of information retrieval
through EMR and ML [46]. There are high expectations for a new wave of ML tools
to revolutionize medicine but researchers must be vigilant for unexpected biases
arising from ML models trained on skewed or bad data.
For an example of bias in EMR driven selection of patients for trial, we look at
the work of Aroda et al. They compared EMR-driven recruitment for type 2 diabe-
tes patient across multiple health centers in the US to that of the traditional manual
method [47]. Although Aroda et al. reported that the EMR-based recruitment had
higher numbers of patients screening, better performance and improved randomi-
zations, they also noticed an association with fewer women and racial minorities
recruited. EMR and electronic-driven recruitment may cause bias in the type of
cohorts identified, as electronically visible individuals are more likely to be identi-
fied and then consent to trials. A skew in this electronic visibility allow only certain
cohort groups to be identified and studied in a clinical trial [48].
These biases arising from ML models are a significant aspect of drug research as
they may cause inadvertent negative effects when these technologies are brought to
market and into the medical centers. This may be the case of poor data sets or a poor
selection of algorithms. In the real world, catch-all algorithms that work in acade-
mia sometimes fail and sometimes there is just not enough data for the data-hungry
machine learning methods. Since manual methods do not suffer due to lack of scale
when ML-based and data-driven research fail when they cannot access big data, the
rise of ML driven processes will not make manual ones totally obsolete.
Another potential for EMR is to extend short, cost-limited trials by electronically
monitoring the cohort after the trial is over. This creates a long term follow up
without the cost associated with a traditional, extended clinical trial. There has been
a successful case in testing novel probiotics to carry out a 5 year follow up, which
would have been too expensive in traditional methods and retention rate increased
due to this electronic method [49]. Furthermore, EMR data may be used in clinical
trials beyond just a follow-up. There is interest in using EMRs as a primary data
source or as a feasibility assessment tool in observational clinical trials, comparative
effectiveness studies and randomized clinical trials [50]. In addition, data can be
used to carry out retrospective cohort studies or population based cohort studies.
Kibbelaar et al. proposed a method to combine data from population-based regis-
tries with detailed EHR to conduct an observational study and reported on a case
study in an hemato-oncology randomized registry trial [51].
These implementations are dependent on the patient’s consent to partake in the
trials and there are studies that investigate the process and ethics of such consent
[52]. Beskow et al. identified patient informed consent as a bottleneck in using EHR
for randomized clinical trials. A study has also identified gaps in ethical responsi-
bility in clinical studies carried out [53]. Furthermore, compliance to security and
privacy regulations is a critical challenge as clinically produced EMRs proliferate
through cloud platforms, mobile devices and commercialized technology. Whilst
security and data protection are of paramount importance when dealing with
EMRs, a discussion of the methods currently in use is beyond the scope of this
chapter. The reader is directed to Refs. [54–56], in which the current technologies
and methods used for security measures on EMRs are reviewed.
To conclude, using data within EMRs can help decrease the cost and time of
clinical trials. First, the section discussed successful examples of EMR mining for
potential recruitment in clinical trials, which included using systems that already
exist in clinical settings, such as BPA and InSite, and tools that employ ML methods.
An advantage with the use of ML methods in clinical trials is the increase in
diversity in trial patients but there is still an issue with the bias that cause inequality
in patient selection. Ultimately, the quality of the ML approach depends on the
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quality of the training data. Therefore, with access to excellent data, EMRs can be
used to extend short, financially limited trials or used as a primary data source to
carry out aspects of data-driven clinical trials. Whilst ML methods are showing
strong performance in enhancing clinical trials, big challenges remain before the
data-driven method replaces the current clinical methodology.
4. EMR use in pharmacovalidation and data mining
However thoroughly a new drug is trialed and tested before it enters the market,
it is possible that there are unknown adverse drug events (ADEs, colloquially
known as side-effects) that manifest on time scales or in ways that cannot be seen in
a clinical trial. Currently, adverse side effects of pharmaceutical products are a
significant source for morbidity and are a significant healthcare cost in many coun-
tries [57, 58]. Therefore, it is vital that pharmaceutical companies undertake
pharmacovigilance, in which they continually track the effects of their drugs after
the drugs deployment. This means that clinical data on post-market drug effects has
a high value to pharmaceutical companies [59]. Post-market surveillance of drugs to
detect, evaluate and prevent ADEs with licensed drugs released in the market is
called pharmacovigilance and is imperative for decreasing negative drug incidents.
Traditionally, medical professionals with domain knowledge would manually
identify ADEs through sources such as clinical trials, health reports, published
medical literature, observational literature and social media [60], which is time
consuming and costly. Therefore, automatically mining these electronic narratives
are an efficient way to identify negative events in the real world setting. Luckily,
real world data on pharmaceutical products and their effects are richly logged in
patient EHRs. To successfully mine the vast quantity of dense data in the EHRs for
drug events, specifically ADEs, studies have focused on the narrative aspect of EMR
and have successfully extracted ADE from both structured [61, 62] and unstruc-
tured [63–65] texts.
This focus on EHR narratives stems from studies that have shown that disease
classification codes, such as ICD, used in EMRs do not encompass the symptoms,
disease status and severity needed for ADE sensitivity and therefore are not appro-
priate in drug event mining [66–68]. Therefore it is necessary to extract more
detailed information from the written text in EMRs, which is achieved using NLP
algorithms. This is a two staged computational task. Firstly, the algorithm must
perform accurate name entity recognition (NER) to identify diseases, drugs, and
negative events in the text, and then it must quantify associations between those
entities, to build a concept of what had occurred [69, 70].
Since 2012, significant developments in statistical analysis, machine-learning
methods and heterogeneous data integration have allowed for automated ADE
detection and offer tools for a novel, automated pharmacovigilance analytics [71].
Some statistical methods such as the odds ratio has been used by Leeper et al. and
Banda et al. to create algorithms designed for extracting drug–ADE associations
from EHRs [72, 73]. However, due to the need to define hypothesis using domain
knowledge, experts in the field were necessary and this suggests a limitation that
these statistical frameworks will not necessarily benefit from having more access to
EHR resources because the core predictors depend on a priori knowledge, which is
static within the algorithm. This means that there is currently still a manual element
required in the process, which limits the scalability of this approach.
Some of the early EMR-narrative studies focused on keyword and phrase driven
identification of general ADE. For example, there are semantic searches specializing
in certain disease targets such as the work done by Ferrajolo et al. who looked at
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drug related acute liver injury [74, 75] and Pathak et al. who mined for DDI between
cardiovascular and gastroenterology pharmaceutical products [76, 77]. Although
these disease specific searches may increase ADE detection in a certain medical
domain, this tailored approach is not scalable or translatable to other diseases. In
terms of identifying general ADEs without a target disease, Honigman et al. devel-
oped a search method using the Micromedex M2 D2 (Micromedex, Denver, Colo-
rado) medical data dictionary to semantically associate drugs and drug classes to
their negative effects and successfully showed the viability of keyword searches on
EMRs [78, 79]. Chazard et al. went a step further to demonstrate searches on a
variety of data structures such as drug administration records, laboratory results,
and other clinical records to successfully detect general ADEs within free texts
[80, 81]. These previous methods successfully identified general ADEs, but key-
word driven searches are now considered simplistic and not scalable, but the suc-
cess of even that method shows that there is great promise for modern techniques.
A further development to keyword-based semantics is a more symbolic rule-based
search that looks for semantic patterns around drug and ADE entities. These symbolic
rule-based searches allow for more information on dosage and non-standard termi-
nologies to be identified during queries and are more capable of general ADE recog-
nition [82–85]. With the rise of semantic research in the medical space, biomedical
NER and NLP has been developed to aid clinical semantic searches and there are
several open sources available, which have been adapted for ADE identification such
as MedLEE [86], MetaMap [87], cTAKES [88, 89], MedEx [90], and GATE [91]. Of
those, MedLEE and MetaMap are two of the most widely used, particularly in the
pharmacovigilance space, where researchers extract Unified Medical Language Sys-
tem (UMLS) concepts from texts using NLP based approaches. Studies have shown
the adaptability of these already available NLP systems. Banerjee et al. used grammar
rules to extract all noun entities and then used MetaMap to semantically identify the
type of entity found. This study found that medications are easily found as entities,
but the model had difficulty in extracting symptoms from laboratory test results as
they vary in length and word choices [92]. In adapting these NLP systems, each study
hit limitations of each source and in particular these tools are not very capable in
temporal resolution, which makes it difficult to distinguish drugs that cause ADEs
from those products that indicate the presence of an ADE.
This shortcoming in temporal resolution has pushed for another wave of studies.
In understanding the use of medication and mentions of diseases, the context
surrounding these entities will determine whether the drug was or was not used at a
time before or after an adverse incident. Some studies have created time stamps on
event entities and medication administration in order to exclude situations where
the adverse symptom was an already existing condition at drug administration, the
ADE was due to another drug, the drug did not cause the ADE and is mentioned as a
negative association, or the pharmaceutical product was given as treatment to the
ADE [84, 93, 94]. Although time resolution on ADE events increase the accuracy of
adverse incident detection, the vagueness and implicit tendency in the human
language to describe temporal events remain as bottlenecks [95].
A great example to illustrate a collaborative ML research on clinical EMRs is the
MADE1.0 challenge carried out in the US. This ML challenge illuminated the popu-
larity and effectiveness of deep neural networking learning in identifying negative
drug incidents, as these models counted for most submissions to the competition.
4.1 MADE1.0 challenge: pharmacovigilance on cancer patient EMRs
In the US, death due to a drug incidence is one of the top six causes of death with
around 2–5% of hospitalized patients suffering from ADEs; in each case an adverse
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event can increase healthcare cost by more than $3200 [96]. Traditionally, ADE-
based pharmacovigilance is done by domain experts reading information on causal-
ity of drugs on incidents and temporal data on these events buried in the clinical
narrative. However, this manual method is not scalable and very costly. To tackle
the significant health and financial strain caused by ADEs, US research institutions
participated in a machine learning challenge to develop methods automate real-time
drug safety surveillance.
In 2018, University of Massachusetts (UMass) hosted a public NLP challenge to
detect Medication and Adverse Drug Events from Electronic Health Records
(MADE1.0). UMass provided 1092 longitudinal EHR notes, which were
anonymized from 21 cancer patients from the University of Massachusetts Memo-
rial Hospital. This EHR resource was rich with information on diseases, symptoms,
indications, medications and relationships between these entities. Three main tasks
were defined in this challenge: (1) named entity recognition (NER), which extracts
drug medications, their attributes (dosage, drug administration, duration, etc.),
disease indications, ADEs and severity, (2) relation identification (RI), which cre-
ates associations between entities, namely drug-indication, drug-ADE, and
medication-attribute relations, and (3) the joint task that assess the NLP model’s
ability to perform both NER and RI. More detailed information on the challenge can
be found at [96]. Jagannatha et al. reported that out of the 11 participating teams the
highest F1 scores in each category was 0.8290 in NER, 0.8684 in RI, and 0.6170 in
NER + RI, where the F1 score is the weighted mean of precision and recall with
ranges from 0 (worst) up to 1 (best) [97].
Within NER task models, the main task can be distilled down to tokenizing
sentences, so the tokens can then be labelled as specified entities. One common
framework for NER is the hidden Markov model (HMM), in which the system is
assumed to be the product of an unknown Markov process, which can then be
statistically modelled. Conditional random fields (CRFs) are related to HMMs,
however they differ in that, unlike HMMs, they are discriminative and classify
labels by drawing decision boundaries. Unlike HMM, CRF does not have strict
independence assumptions, which makes the model more flexible but highly com-
plex at the training stage, meaning that retraining is more involved than that of the
HMM [98]. The other main class of model is the neural network, including
convolutional neural networks (CNN) and recurrent neural networks (RNN). Long
short-term memory (LSTM) is an RNN architecture in common use for NER pur-
poses. It is designed for classifications and predictions on time series data, in which
events may occur with significant and unknown time lags in the sequence [99].
Teams involved in the MADE1.0 challenge used pre-trained embeddings to prepare
the RNNs or as feature inputs into CRF training [97]. Within NER task models in
this challenge, conditional random fields (CRF) and long short-term memory
(LSTM) were among the most frequently used frameworks [97].
In the NER category, team WPI-Wunnava scored the highest scores with
F1 = 0.8290 [97]. Wunnava et al. created a system called the Dual-Level Embed-
dings for Adverse Drug Event Detection (DLADE) to tailor to the NER task [100].
In the challenge, the NER task is limited to certain standard resources like NLTK,
Stanford NLP, and cTakes for the text pre-processing for fairness of the participants
with varying accessibility to resources. In particular, DLADE used training data and
word embeddings provided by the challenge organizer as part of the publicly
released resources. Wunnava et al. developed the system with a rule-based
tokenizer, which first tokenized sentences, and then entities within sentences,
where entities may be multiple words. The system then uses a combination of
bi-LSTM, a model that examines the text sequence in the forward and reverse
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direction to extract contextual representation, for the initial two layers responsible
for the character embedding and the word embedding but employed a linear-chain
CRF for the output layer [100]. Wunnava et al. concluded that their dual-level
character and word embedding method was a better approach compared to the
simple word-embeddings by showing a statistically significant (p < 0.05 and
p < 0.01) improvement in F1-score over multiple entities (ADE, drug, dose,
duration, etc.) [100]. However, many challenges remain when identifying
multi-worded entities, unknown abbreviations, ambiguous differentiation between
entities such as indication vs. ADE, and uses of colloquial or non-medical jargon.
In both the RI and NER-RI tasks, the process can be simplified to a classification
problem, where entity pairs are in a certain class of relationships. Research teams
used a variety of approaches to the RI tasks. As well as neural network methods,
they also used random forest classifiers, in which an ensemble of decision trees is
used and the aggregate score from the committee of decision trees decides the
output class. Support vector machines (SVM) were another popular tool; they are
optimizing algorithms that maximize the margin between the support vectors
(input data) and the decision hyperplane [101].
In the RI category, team UofUtah-Patterson score the highest scores with
F1 = 0.8684 [97]. Chapman et al. treated the RI task as a two-step supervised
classification problem and employed random forest models implemented on scikit-
learn to identify true relations between entities and to class the type of relation of
the identified pair [102]. Their source code for their models submitted to the
MADE1.0 challenge can be found on their github page [103] and details on the
model architecture is authored at [104].
In the NER + RI category, team IBMResearch-dandala obtained the highest
integrated task score (F1 = 0.6170) by harnessing bidirectional long short-term
memory (BiLSTM) and CRF neural network for medical entity recognition, and a
combined BiLSTM and attention network for relation extraction [97]. Dandala et al.
reported that NER was achieved at high accuracy (F = 0.83) and RI measured an F
score of 0.87 achieved by adding joint modelling techniques and using external
resources as extra data inputs [105]. However high the individual F score, the
overall integrated task only reached 0.6170, which suggests the need for domain
knowledge to increase accuracy in ADE detection.
The MADE1.0 challenge highlights the potential for developing pharmacov-
alidation based on ML methods with very high performance in categories such as
NER and RI, which are crucial in automated ADE extraction from EMRs. At the
time of completion of the MADE1.0 challenge, Jagannatha et al. suggested two
broad approaches to further improve the challenge’s outcomes [97]. First, to work
on designing methods that include external knowledge and unlabeled text, which
suggests the potential for unsupervised learning. The second point was to increase
efforts in higher volume, labelled corpus to train the models on, but this does not
solve the issue of algorithms failing to adapt to the messy, real world EHRs, an
inevitable encounter in commercial use. Not only did this challenge show success in
developing ML-based pharmacovigilance but also demonstrated the power of
collaboration and influenced other groups to further ADE research.
4.2 Further ML works and trends on pharmacovigilance
After the MADE1.0 challenge, an even further increase of available EHR
resources has pushed researchers to develop robust ML methods, which are inher-
ently data hungry and are predisposed to the vast amount of information provided
by clinical texts. There is a study that builds on the MADE1.0 challenge and shows
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the potential for deep learning models on EHR to extract ADE measures to help
with pharmacovigilance. To try to solve the issue of under-reporting within the
FDA Adverse Event Reporting System, Li et al. employed deep learning models
and multi-task learning (MLT), in particular, hard parameter sharing, parameter
regularization, and task relation learning, for ADE detection [106]. They used the
MADE 1.0 challenge corpus, 1089 high-quality EMRs from oncology patients, for
training and validation of their model. A BiLSTM conditional random field network
was used for entity recognition and a BiLSTM-Attention network for entity relation
extraction. Li et al. reported that the deep learning produced a F1 = 0.65 for the
NER + RI task and this score was further improved through the hard parameter
sharing MLT method to F1 = 0.67, whereas the other two MLTs did not improve
performance. This study successfully built upon the findings from MADE1.0
and further improved the performance of the NER + RI task to show potential in
this area.
Some ML trends that extract medically actionable results are the popularity of
CRFs, SVMs, and random forest models. CRFs and SVMs may be used on languages
beyond English. For example, Aramaki et al. studied Japanese clinical records and
found that ADE were found in 7.7% of EHRs, out of which 59% can be automatically
extracted [107]. They used CRFs and SVMs to determine whether a detected drug
and adverse event pair was an ADE, which gave a 0.411 precision and 0.917 recall.
In contrast, random forest models have been popular due to its reliable performance
and explainability of the classifications when compared with other “black-box”
models such as SVMs. Studies by Henriksson et al. andWang et al. has used random
forests for classification of entities and identify ADEs [108, 109]. Explainability of
models is an often undervalued aspect of ML, but is valuable in the medical space.
Overall, despite the many challenges, data-driven pharmacovigilance has advanced
at an incredible pace owing to the mixture of funded challenges and developing ML
methods and shows much promise to improve healthcare.
5. Drug repurposing
It is worth mentioning that EMR data can be mined for drug repurposing indi-
cations. The idea behind drug repurposing is to see whether existing, licensed drugs
may have therapeutic benefits for conditions other than what they were designed
for. Data-driven analysis is evidently key in this regard as it can detect drug
response signals. Drug repurposing is different from the traditional drug discovery
because data-driven analysis lacks a hypothesis for the indication intended to be
treated or for the targeted biology. In other words, studies examine machine learn-
ing methods to see whether data-centric analysis can help create new hypothesis,
which may either be a completely random and biologically impossible statement or
a novel signal worthy of scientific investigation. Since drug repurposing only needs
medical data and analytics, it is a cheap and quick alternative to the traditional drug
discovery stages, which require basic research, pre-clinical research, clinical trials,
and finally the review and approval of the pharmacogenomic product. The potential
of drug repurposing is highly anticipated as this method requires big data and an
increasing amount of digitized medical records such as EHRs are made available.
It is a particularity popular topic in recent years as data-hungry machine learning
tools develop and high-throughput server less machines are made cheaper and
more accessible through cloud computing services such as AWS, Google Cloud
Platform, and Microsoft Azure, to name a few. For a more in-depth discussion of
oncology drug repurposing using data from EMRs, the reader is directed to Refs.
[110–112].
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6. Case studies in different countries
6.1 Oncology precision medicine in the US and Japan
Another anticipated but still young area is the possibility of precision medicine
using individual genomic data. Cancer is an accumulation of genetic alternations
within the cell and, oncogenetic or cancer-developing genes are called driver genes.
Identifying driver genes within the genome and delivering the optimal treatment to
such cancer-related targets is known as precision medicine. However, there is a vast
amount of data within even a single individual’s genome and finding variants
becomes the key challenge in order to pinpoint the best pharmacological treatment
for an individual based on their genetic background. Harnessing the combination of
data from already existing genomic variant databases and historic clinical data from
EMRs, researchers aim to find such cancer-related variations and driver genes. In a
few countries, studies revolving around the interaction between the genome and
cancer treatment drugs have gained much attention.
In the US, the NCI-MATCH trials, a phase II precision medicine cancer trial
initiated in 2015, showed negative results in precision medicine and concluded that
the genomic data did not correlate with any significant results in drug variation [113].
This low statistical significance is not surprising from a data mining perspective as
numbers of patients accrued for each of the +40 arms within this study were very
small, ranging from 4 to 70 people [114]. Furthermore, the majority of the recruited
patients (62.5%) had rare tumors that were not the four most common cancers
(breast, colorectal, non-small cell lung, and prostate) [115]. This diversity in cancer
types may have introduced confounding factors that affected the statistics of the trial.
In Japan, starting 2018, the Japanese Ministry of Welfare and Labor is sponsor-
ing a panel trial on partial genomic testing for oncogenetic variation. This partial
genomic testing aims to reveal the best and optimal cancer drug treatment on the
individual based on their genetic variations. In 2019, 11 Cancer Genomic Core
hospitals and central medical institutions were selected to start collecting genomic
data and clinical data in preparation for a nation-wide genomic panel trial [116].
Under the funding of the country’s National Health Insurance, it strives to predict
cancer patient treatment responses based on their partial genome data.
There is a complex interplay between intricate biological systems and the NCI-
MATCH trial illustrates that precision medicine methods need much more devel-
opment before they can pin point a certain genomic sequences to the onset of
cancer. Some have voiced pessimistic views that this precision medicine task is not
feasible and overly-costly at this point in time [117]. However, precision medicine is
in the horizon. With more data samples, similar research can yield more insight into
precision medicine.
In the future, individual whole genome data may be regular practice to include
as part of EHRs in order to help deliver the optimal cancer treatment. Currently,
there is a bottleneck where there are not enough types of commercialized cancer
drug against which to test the genomic variation and to find which treatment works
best on an individual. As all aspects of EMR-driven research converge, more med-
ical data will be collected, stored and published. This will lead to already available
commercial drugs undergoing more comprehensive pharmacovigilance and real-
world data will effectively drive new drug research. Therefore, it is likely that more
types of cancer pharmacology products will become available. Furthermore, the
efforts in using ML to mine EMRs may lead to AI predicting cancer patient disease
trajectories. The trend toward using NLP to extract relevant information from
unstructured EMRs and harnessing deep learning could help reproduce drug-
related clinical decision making carried out by medical professionals [110, 111].
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6.2 Open sourced resources using EMRs in the UK
In England, there are trusts and clinical commissioning groups who oversee how
providers such as hospitals and clinics use their resources. A problematic bottle-
necks are that different trusts use different EMR platforms, which have little
national standardization and do not allow for interprovider access, which especially
cause problems when patients switch trust domains.
A remedy to this lack of standardization is the use of open sourced, publicly
available resources including de-identified EMR data. Evident from the data-
hungry nature of ML methods and their demonstrated need in scalable phenotype-
genotype association research, publicly available EMRs play a crucial role in the
advancement of this field. Some notable open sourced data sources and tools
include the UK Biobank, where 50,000 individuals (aged 40–69) were recruited
from England, Wales, Scotland [118]. The biobank includes detailed phenotype and
genotype data, lifestyle surveys, pathophysiological data and imaging data on each
individual [118]. Once a centralized, open-sourced EMR data is made available, the
next step is the development of platforms that interact with said resource.
The CArdiovascular disease research using LInked Bespoke studies and
Electronic health Records (CALIBRE) portal offers freely available software that
provides tools and algorithms, which is research ready and have already extracted
variables extracted from various EMRs. Phenotype algorithms contained in CALI-
BRE, which employs data from the UK Biobank, are rule based and use phenotype
validations like etiological, which use external published evidence to support the
algorithm; prognostic, which evaluate the event’s similarity to already existing
scientific knowledge; case-note review, which compares the positive predictive
value (PPV) and the negative predictive value (NPV) against a gold standard like a
clinician’s notes; cross-EHR-source concordance, which checks the consistency in
findings across other EHRs; genetic, which double checks whether there is consis-
tency in genetic associations and external populations, which validates by compar-
ing results to similar studies done in different countries [119]. These phenotype
validations, and standardized validation systems in general, are crucial in charac-
terizing ML algorithms since variations in training data can alter outputs even when
the ML method does not change. As open source data proliferates, freely available
validation methods may grow in a parallel manner.
In addition, openEHR is also a platform that pools industry specifications, clin-
ical models and software that are intended for data science solutions in the
healthcare space. OpenEHR was founded in 2003 by an international non-profit
organization and maintained by individuals around the world [120]. In 2017, the
UK became the first country to introduce infrastructure from openEHR into the
main healthcare system to streamline phenotype data collection and vendor-neutral
clinical data storage from all the trusts participating in the 100,000 genome project
[121]. Newly coordinated pipelines of additional EHR data such as those from the
NHS will increase the through-put in openEHR, which in turn develops the best
tools to handle big data, which then completes the circle by promoting the use of an
ever increasing amount of medical data. This data-driven vision, in which an open
community encourages cooperation by open access and pools existing knowledge
around EMR-driven healthcare, will certainly accelerate the evolution of ML
methods.
6.3 EHR databases in Estonia
Estonia is one of the world-leading countries in terms of the nationwide system-
atization of digital medical documentation and the high quality of EHRs. By the end
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of 2014, Estonia had centralized EHR access via a single portal, where over 99% of
the population could view their own medical records [122]. This is a remarkable
statistic but more notably, Estonia’s EHR vision had already been initiated in 2007
when the Estonian Genome Center of the University of Tartu established the foun-
dations of the Estonian biobank, which includes 52,000 participants worth of
genomic and health data representing about 5% of the adult population of Estonia
[123, 124]. Seven years later, the Estonian biobank was linked to the Estonian
National Health Information System (ENHIS), which included 44,000 inpatient
and 212,000 outpatient medical summaries, EHRs and digital prescriptions from all
medical service providers [124]. Since the merge, the databases have been updated
through periodic additions of EHRs. By 2016, Estonia was ranked within the top
three countries to have the best capability of effectively deploying, operating,
maintaining and supporting statistical and medical research using EHRs by the
HCQI Survey of Electronic Health Record System Development and Use [125]. This
extensive data collection was made possible by the national electronic identification
card (ID-card) as this chipped ID-card was made compulsory and became part of
the national infrastructure [126]. As result of these efforts, Estonian EHR databases
are highly valuable sources for researching EHR-driven methods.
An ADE study using Estonian EHR databases by Tasa et al. demonstrates the
database’s ability to conduct high impact, translational research. The whole-genome
sequencing (WGS) data of +2200 Estonian Biobank participants and the EHRs of
the sequenced individuals were taken from Health Insurance Fund Treatment Bills,
Tartu University Hospital and North Estonia Medical Center databases [127]. EHRs
were mined using ICD codes to find ADE occurrences and a mixture of the ICD and
manual verification methods was used to identify associations between genetic
polymorphisms and ADEs [127]. Associations between genetic variations and drug
responses are vital in advancing personalized drug treatment, which is also referred
to as pharmacogenomics. Important genes within the study of pharmacogenomics
are called pharmacogenes. The study reported 29.1  106 novel variants. To priori-
ties genetic analysis, Tasa et al. compiled 1314 loss-of-function, missense, and
putative high-impact variants in promoter regions of 64 pharmacogenes [127]. They
reported that 80.3% of the variants were rare (MAF < 1%), and this high propor-
tion suggests that gene variation is crucial in understanding pharmacogenomics
[127]. Next, the study combined EHRs to the genetic data to extract 1187 partici-
pants with potential ADEs. As a validation, Tasa et al. replicated pharmacogenetic
associations between the CYP2D6*6 allele and tramadol related ADEs (p = 0.035;
odds ratio [OR] = 2.67) and between the same allele and amitriptyline induced
ADEs (p = 0.02; OR = 6.0) [127]. In addition, they replicated four more validated
pharmacogenetic associations and discovered nine independent, new gene associa-
tions with ADEs in a group of individuals divided by drug prescriptions. Notably,
they identified a new association between CTNNA3 and myositis for oxicam-
treated participants. This study demonstrated the viability of layering EHR and
WGS data at a population-based scale in order to advance pharmacogenomic.
Beyond the scope of this study, identifying pharmacogenomic associations relies
more and more on big-data driven projects that looks for genetic variants in differ-
ent communities and highlights variants that can be medically targeted to advance
healthcare [128–130].
In summary, Estonia’s world-leading efforts to integrate EHRs as a method to
feedback data to basic research is a possible future of data-driven healthcare medi-
cine, which focuses on digitization with a vision for translational biomedical
research. Estonia created a data-mining driven database, in which different aspects
of the EHRs are linked an ID-card. Although different implementations will be
necessary to replicate Estonia’s rich and accessible EHR database, Estonia sets a
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precedent to the rest of the world and demonstrates the positive biomedical impli-
cations of such well-organized databases of rich EHR sources.
7. Conclusion
In the past decade, EMRs have become a vital data source in advancing
healthcare. In the context of AI, EMRs are highly attractive because there is a vast
quantity of rich and variable data types which cannot be processed manually. In the
context of biomedical research, EMRs have exciting potential for impactful medical
applications, but only if actionable biomedical conclusions can be accurately
extracted. In the clinical context, EMRs were introduced to replace the traditional
paperwork but were not intended for data-mining research; they were never
intended to perform anything that paper documents were not designed to do.
Having been introduced in a time before the phrase “machine learning”, digitiza-
tion of medical records has far surpassed the imagined benefits of this transition.
Envisioned as a direct replacement of paper records, EMR history has been fraught
with difficulties: implementation costs, workflow disruptions and cyber-attacks to
name a few. Harnessing EMRs for research purposes marks a milestone in transla-
tional biomedical medicine. It is the intersection of basic science, data-driven
methods and clinical research where healthcare is transformed: every hospital visit
improving human knowledge of diseases one EMR at a time.
The chapter started with a discussion of the EMRs definition, given that they
have been introduced with little regard to compatibility with other existing EMR
systems. There are many issues that hospitals can encounter when transitioning
from paper records to electronic, however, efficiency gains from digitizing records
are significant even without the use of big data. To exemplify what can be achieved
by applying ML techniques to the data contained in EMRs, three key biomedical
research areas were considered: phenotype-genotype association, clinical trials for
new drug and pharmacovigilance studies.
Adopting high throughput data strategies into clinical drug trials can reduce the
inefficiencies that often plague such trials. EMR mining using already existing
systems can improve trial recruitment, but care must be taken to reduce potential
bias in patient selection. Additionally, EMRs can be employed to continue data
collection after the trial formally ends, a great benefit for financially limited trials,
or they can even be treated as a primary data source as long as the data is considered
to be of satisfactory standard.
After a drug undergoes clinical trials and is approved for market launch, phar-
maceutical companies are encouraged to continue drug surveillance to detect, eval-
uate and prevent adverse drug events, which create medical and financial burdens.
Such surveillance can be cheaply and efficiently done by continually mining EHR
narratives. In the context of ADE detection, keyword searches are considered to be
too simplistic and to lack scalability. Despite this, they still show some success in
small scale studies, serving as a proof of concept that harnessing EHRs with more
advanced processes could greatly benefit pharmagovigilance. However, NLP
based-approaches performed much better than keyword-based methods and an
excellent case study on NLP-driven pharmacovigilance is the MADE1.0 challenge.
By bringing together multiple institutions, the challenge succeeded in developing
high performing ML methods, including frequent usage of CRFs and LSTM,
for the NER and RI tasks. This initiative promoted further works to create even
more robust ML methods to extract ADEs from oncology EMRs and reflects the
overall trend in the pharmacovigilance space toward CRF, SVM and random forest
models.
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With this vital context on how ML methods are used to analyze the data within
EMRs, some selected international case studies on EHR-driven research were
presented. Firstly, on the outlook of oncology precision medicine: NCI-MATCH
trials in the US concluded that no drug response is correlated with genomic data,
whilst preparation for partial genomic testing for oncology drugs is underway in
Japan. Despite negative results nation-wide initiatives may spur on the collective
development of drug research. Secondly, UK-based open source resources for EHR
manipulation, were discussed, both large consolidated datasets and freely available
tools, algorithms and platforms. This vision for open sourced resources is a valuable
digital environment in which to pool technical knowledge, especially because of the
translational and multi-disciplinary dimension of extracting medically meaningful
conclusions from EHRs. Thirdly, the EHR databases set up in Estonia were
reviewed, which are both nationally extensive and high quality. This set up the
groundwork to deploy a population-based WGS and EHR combinatory study con-
ducive to pharmacogenetic advances. Estonia’s databases demonstrate the power of
harnessing data from EHR for the progress of healthcare.
In contrast to the recent advancement and current interest in clinically-applied
deep learning, there is still no definitive evidence of a model with predictive per-
formance that is similar to a human physician [131]. As of 2020, there is no imme-
diate vision in which AI can fully automate drug research pipelines or
independently diagnose and provide subsequent health care procedures making
researchers and clinicians obsolete. As we have seen, however, there is ample
evidence that EMRs will increasingly play a vital role in all aspects of the drug
research arc from fundamental science and clinical trials to post-market surveil-
lance.
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